+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Devic's Syndrome Treatment Market - Global Forecast to 2030- Product Image
Devic's Syndrome Treatment Market - Global Forecast to 2030- Product Image
Sale

Devic's Syndrome Treatment Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5977777
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Devic's Syndrome Treatment Market grew from USD 220.27 million in 2024 to USD 230.71 million in 2025. It is expected to continue growing at a CAGR of 4.70%, reaching USD 290.17 million by 2030.

Devic’s syndrome, also known as neuromyelitis optica spectrum disorder (NMOSD), presents a complex clinical challenge characterized by severe relapses affecting the optic nerves and spinal cord. Recent advances in immunopathology have uncovered specific autoantibody targets, paving the way for targeted therapies that significantly improve patient outcomes. Despite this progress, treatment pathways remain fragmented due to variable patient responses, evolving diagnostic criteria, and emerging regulatory requirements across regions. As stakeholders strive to optimize care and manage escalating costs, a holistic understanding of market drivers and inhibitors becomes indispensable. This executive summary distills critical insights into shifting therapeutic paradigms, tariff impacts, and segmentation nuances, equipping decision-makers with actionable intelligence. By synthesizing the latest industry developments and stakeholder priorities, including patient advocacy groups and regulatory bodies, the following analysis serves as a strategic blueprint to navigate the dynamic Devic’s syndrome treatment landscape.

Transformative Shifts in the Devic’s Syndrome Market

The past five years have witnessed transformative shifts reshaping the Devic’s syndrome market. Precision immunotherapy has emerged from the research pipeline into clinical practice, with humanized monoclonal antibodies demonstrating durable remission rates. Concurrently, breakthroughs in plasmapheresis protocols and advanced physical therapy modalities have expanded therapeutic arsenals, enabling multidisciplinary care teams to tailor interventions. Regulatory agencies have accelerated approval pathways for orphan indications, fostering earlier patient access to cutting-edge biologics and recombinant fusion proteins. Equally, digital health solutions now facilitate remote monitoring of relapse indicators, while real-world evidence platforms quantify long-term outcomes. These converging forces have not only elevated clinical standards but also recalibrated competitive dynamics, prompting established pharmaceutical players and nimble biotech firms to forge strategic alliances. As a result, market participants must stay agile, anticipating ongoing innovation cycles and aligning commercial strategies with evolving reimbursement frameworks.

Cumulative Impact of United States Tariffs 2025

The introduction of new United States tariffs in 2025 targeting key active pharmaceutical ingredients and specialized reagents has had a cumulative effect on both cost structures and supply chains. Import duties on monoclonal antibody production materials prompted several developers to reassess procurement strategies, driving some to secure alternative sources in Europe and Asia-Pacific. Increased duty burdens have translated into higher ex-factory prices for injected medications and intravenous infusions, compelling payers to negotiate stricter formulary placements for biologics and immunosuppressants. Meanwhile, cost pressures have accelerated onshore production investments, as manufacturers seek to mitigate tariff volatility through localized facilities. Although short-term margins feel the strain, longer-term benefits are emerging from enhanced domestic capacity and reduced lead times. In response, stakeholders are engaging in collaborative dialogues with policymakers to advocate for duty exemptions on orphan disease therapies, underscoring the critical importance of sustained innovation in rare neurological disorders.

Key Segmentation Insights

A nuanced analysis of treatment- and patient-focused segments reveals diverse growth opportunities. Based on treatments, the market splits into pharmaceuticals-encompassing injected, intravenous, and oral medications-and therapies such as immunotherapy, physical therapy, and plasmapheresis, each responding differently to pricing dynamics and clinical adoption rates. Patient demographics further refine potential outreach, with adult, geriatric, and pediatric populations demonstrating varying tolerance profiles, while female, male, and non-binary patients face unique diagnostic journeys, and those in high-, middle-, and low-income brackets navigate disparate access barriers. Distribution channels map onto clinics, including general and specialized neurology practices, hospitals structured as private or public institutions, and the burgeoning online pharmacy sector. End-use settings extend beyond hospitals and clinics into home care-both assisted and self-administration models-and medical research facilities driving next-generation trials. Drug classifications span biologics-ranging from humanized monoclonal antibodies to recombinant fusion proteins and therapeutic monoclonal antibodies-through corticosteroids applied in maintenance or pulse regimens, to immunosuppressants utilized for induced remission or maintenance therapy. Insurance coverage divides between government programs and private insurers offering full or partial coverage, significantly influencing patient uptake. Treatment goals bifurcate into disease modification strategies focused on progression control and relapse prevention, alongside symptom relief initiatives targeting mobility improvement and pain management. Finally, diagnosis tests separate into blood assays detecting anti-AQP4 antibodies versus routine panels, and MRI scans encompassing both brain and spinal imaging, guiding precision treatment plans.

Key Regional Insights

Regional dynamics in the Devic’s syndrome treatment market highlight differentiated growth trajectories and regulatory landscapes. In the Americas, robust research infrastructure and a mature payer ecosystem drive rapid adoption of advanced biologics, supported by patient advocacy networks that facilitate clinical trial enrollment. Europe, the Middle East & Africa exhibit regulatory harmonization efforts and cost-containment pressures, leading to collaborative procurement schemes and greater emphasis on generics and biosimilars. Meanwhile, Asia-Pacific registers the fastest overall expansion, fueled by rising awareness, strengthening healthcare infrastructure, and strategic investments in domestic manufacturing of recombinant proteins and immunosuppressants. Local partnerships and tailored reimbursement models are accelerating access in high-growth hubs such as India, China, and Southeast Asia, creating a dynamic interplay between global innovators and regional stakeholders.

Key Companies Insights

Market competition is shaped by a diverse array of global and regional players. Accord Healthcare, Inc. leverages its generics expertise to offer cost-effective corticosteroid regimens, while Alexion Pharmaceuticals, Inc. by AstraZeneca PLC continues to pioneer complement inhibitors for rare antibody-mediated conditions. Anant Pharmaceuticals Pvt. Ltd. and Apple Pharmaceuticals focus on scaling injectable and oral therapies across emerging markets. Cadila Pharmaceuticals Limited maintains a robust pipeline of immunosuppressants, complemented by Chugai Pharma Taiwan Ltd.’s niche biologic research. Conscientia Industrial Co., Ltd. supplies critical plasmapheresis equipment, and Evidentic GmbH drives innovation in anti-AQP4 testing. F. Hoffmann-La Roche Ltd. remains a leader in advanced monoclonal treatments, with Healthy Life Pharma Pvt. Ltd. targeting affordability in under-served regions. Horizon Therapeutics plc by Amgen, Inc. expands novel antibody portfolios, while LEXICARE PHARMA PVT. LTD. and Merck KGaA invest heavily in developmental biologics. Mitsubishi Tanabe Pharma Corporation enhances strategic collaborations, and Opexa Therapeutics, Inc. explores cellular approaches. Samsung Bioepis Co., Ltd. by Samsung Biologics scales biosimilars production, as Teva Pharmaceutical Industries Ltd. repurposes legacy molecules. TG Therapeutics, Inc. introduces next-generation agents, supported by diagnostic partnerships with Thermo Fisher Scientific Inc., and West-Ward Pharmaceuticals Corp. by Hikma Pharmaceuticals PLC emphasizes specialty generics distribution.

Actionable Recommendations for Industry Leaders

Industry leaders should adopt a multi-pronged strategy to capitalize on emerging opportunities. First, diversifying supply chains across tariff-exempt regions and onshore facilities will hedge against future duty shifts and ensure uninterrupted access to critical reagents. Second, investing in next-generation biologics and biosimilars pipelines-particularly humanized monoclonal antibodies and recombinant fusion proteins-will address escalating demand for high-efficacy therapies. Third, integrating digital health platforms for remote monitoring and real-world evidence collection can differentiate offerings and strengthen payer negotiations. Fourth, forging alliances with patient advocacy groups will enhance trial recruitment and expedite market entry, while collaborative engagements with payers should prioritize innovative reimbursement models aligned with disease modification outcomes. Finally, tailoring programs to underserved demographic segments and home care settings will expand market penetration, positioning organizations for sustainable growth.

Conclusion

The evolving Devic’s syndrome treatment landscape underscores the importance of strategic agility. Recent shifts in regulatory policy, tariff pressures, and segmentation complexity reveal that success hinges on integrated approaches combining product innovation, operational resilience, and patient-centric care models. Stakeholders who proactively address supply chain vulnerabilities and embrace data-driven decision-making will seize leadership positions, while those who neglect emerging demographic and regional nuances risk ceding ground to more adaptive competitors. As the market enters its next growth phase, continuous collaboration among researchers, clinicians, manufacturers, and payers will be critical to advancing therapeutic frontiers and ensuring equitable access for all patients.

Market Segmentation & Coverage

This research report categorizes the Devic's Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Pharmaceuticals
    • Injected Medications
    • Intravenous Medications
    • Oral Medication
  • Therapies
    • Immunotherapy
    • Physical Therapy
    • Plasmapheresis
  • Age Group
    • Adult
    • Geriatric
    • Pediatric
  • Gender
    • Female
    • Male
    • Non-Binary
  • Socioeconomic Status
    • High Income
    • Low Income
    • Middle Income
  • Clinics
    • General Clinics
    • Specialized Neurology Clinics
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Online Pharmacies
  • Home Care
    • Assisted Care
    • Self-Administration
  • Hospitals and Clinics
  • Medical Research Facilities
  • Biologics
    • Humanized Monoclonal Antibody
    • Recombinant Fusion Protein
    • Therapeutic Monoclonal Antibody
  • Corticosteroids
    • Maintenance Therapy
    • Pulse Therapy
  • Immunosuppressants
    • Induced Remission
    • Maintenance Therapy
  • Government Programs
  • Private Insurance
    • Full Coverage
    • Partial Coverage
  • Disease Modification
    • Progression Control
    • Relapse Prevention
  • Symptom Relief
    • Mobility Improvement
    • Pain Management
  • Blood Tests
    • Anti-AQP4 Antibodies
    • Routine Blood Test
  • MRI Scans
    • Brain MRI
    • Spinal MRI

This research report categorizes the Devic's Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Devic's Syndrome Treatment Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Accord Healthcare, Inc.
  • Alexion Pharmaceuticals, Inc by AstraZeneca PLC
  • Anant Pharmaceuticals Pvt. Ltd.
  • Apple Pharmaceuticals
  • Cadila Pharmaceuticals Limited
  • Chugai Pharma Taiwan Ltd.
  • Conscientia Industrial Co., Ltd
  • Evidentic GmbH
  • F. Hoffmann-La Roche Ltd
  • Healthy Life Pharma Pvt. Ltd.
  • Horizon Therapeutics plc by Amgen, Inc.
  • LEXICARE PHARMA PVT. LTD.
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Opexa Therapeutics, Inc.
  • Samsung Bioepis Co., Ltd. by Samsung Biologics
  • Teva Pharmaceutical Industries Ltd.
  • TG Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • West-Ward Pharmaceuticals Corp. by Hikma Pharmaceuticals PLC

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Devic's Syndrome Treatment Market, by Treatments
8.1. Introduction
8.2. Pharmaceuticals
8.2.1. Injected Medications
8.2.2. Intravenous Medications
8.2.3. Oral Medication
8.3. Therapies
8.3.1. Immunotherapy
8.3.2. Physical Therapy
8.3.3. Plasmapheresis
9. Devic's Syndrome Treatment Market, by Patient Demographics
9.1. Introduction
9.2. Age Group
9.2.1. Adult
9.2.2. Geriatric
9.2.3. Pediatric
9.3. Gender
9.3.1. Female
9.3.2. Male
9.3.3. Non-Binary
9.4. Socioeconomic Status
9.4.1. High Income
9.4.2. Low Income
9.4.3. Middle Income
10. Devic's Syndrome Treatment Market, by Distribution Channels
10.1. Introduction
10.2. Clinics
10.2.1. General Clinics
10.2.2. Specialized Neurology Clinics
10.3. Hospitals
10.3.1. Private Hospitals
10.3.2. Public Hospitals
10.4. Online Pharmacies
11. Devic's Syndrome Treatment Market, by End-Use
11.1. Introduction
11.2. Home Care
11.2.1. Assisted Care
11.2.2. Self-Administration
11.3. Hospitals and Clinics
11.4. Medical Research Facilities
12. Devic's Syndrome Treatment Market, by Drug Classifications
12.1. Introduction
12.2. Biologics
12.2.1. Humanized Monoclonal Antibody
12.2.2. Recombinant Fusion Protein
12.2.3. Therapeutic Monoclonal Antibody
12.3. Corticosteroids
12.3.1. Maintenance Therapy
12.3.2. Pulse Therapy
12.4. Immunosuppressants
12.4.1. Induced Remission
12.4.2. Maintenance Therapy
13. Devic's Syndrome Treatment Market, by Insurance Coverage
13.1. Introduction
13.2. Government Programs
13.3. Private Insurance
13.3.1. Full Coverage
13.3.2. Partial Coverage
14. Devic's Syndrome Treatment Market, by Treatment Goals
14.1. Introduction
14.2. Disease Modification
14.2.1. Progression Control
14.2.2. Relapse Prevention
14.3. Symptom Relief
14.3.1. Mobility Improvement
14.3.2. Pain Management
15. Devic's Syndrome Treatment Market, by Diagnosis Tests
15.1. Introduction
15.2. Blood Tests
15.2.1. Anti-AQP4 Antibodies
15.2.2. Routine Blood Test
15.3. MRI Scans
15.3.1. Brain MRI
15.3.2. Spinal MRI
16. Americas Devic's Syndrome Treatment Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Devic's Syndrome Treatment Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Devic's Syndrome Treatment Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Accord Healthcare, Inc.
19.3.2. Alexion Pharmaceuticals, Inc by AstraZeneca PLC
19.3.3. Anant Pharmaceuticals Pvt. Ltd.
19.3.4. Apple Pharmaceuticals
19.3.5. Cadila Pharmaceuticals Limited
19.3.6. Chugai Pharma Taiwan Ltd.
19.3.7. Conscientia Industrial Co., Ltd
19.3.8. Evidentic GmbH
19.3.9. F. Hoffmann-La Roche Ltd
19.3.10. Healthy Life Pharma Pvt. Ltd.
19.3.11. Horizon Therapeutics plc by Amgen, Inc.
19.3.12. LEXICARE PHARMA PVT. LTD.
19.3.13. Merck KGaA
19.3.14. Mitsubishi Tanabe Pharma Corporation
19.3.15. Opexa Therapeutics, Inc.
19.3.16. Samsung Bioepis Co., Ltd. by Samsung Biologics
19.3.17. Teva Pharmaceutical Industries Ltd.
19.3.18. TG Therapeutics, Inc.
19.3.19. Thermo Fisher Scientific Inc.
19.3.20. West-Ward Pharmaceuticals Corp. by Hikma Pharmaceuticals PLC
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. DEVIC'S SYNDROME TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. DEVIC'S SYNDROME TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. DEVIC'S SYNDROME TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENTS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENTS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNELS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNELS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END-USE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END-USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASSIFICATIONS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASSIFICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT GOALS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT GOALS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DIAGNOSIS TESTS, 2024 VS 2030 (%)
FIGURE 22. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DIAGNOSIS TESTS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DEVIC'S SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INJECTED MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AGE GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY NON-BINARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SOCIOECONOMIC STATUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HIGH INCOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY LOW INCOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MIDDLE INCOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALIZED NEUROLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ASSISTED CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SELF-ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MEDICAL RESEARCH FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HUMANIZED MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RECOMBINANT FUSION PROTEIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTIC MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PULSE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INDUCED REMISSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY FULL COVERAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PARTIAL COVERAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT GOALS, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISEASE MODIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PROGRESSION CONTROL, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RELAPSE PREVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISEASE MODIFICATION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SYMPTOM RELIEF, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MOBILITY IMPROVEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SYMPTOM RELIEF, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DIAGNOSIS TESTS, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ANTI-AQP4 ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ROUTINE BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MRI SCANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BRAIN MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPINAL MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MRI SCANS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT GOALS, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISEASE MODIFICATION, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SYMPTOM RELIEF, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DIAGNOSIS TESTS, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MRI SCANS, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT GOALS, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISEASE MODIFICATION, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SYMPTOM RELIEF, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DIAGNOSIS TESTS, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MRI SCANS, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT GOALS, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISEASE MODIFICATION, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SYMPTOM RELIEF, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DIAGNOSIS TESTS, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MRI SCANS, 2018-2030 (USD MILLION)
TABLE 161. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 162. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 163. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 164. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 165. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 166. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 167. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 168. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 169. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 170. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 171. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 172. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 173. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 174. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 175. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 176. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 177. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 178. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, 2018-2030 (USD MILLION)
TABLE 179. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT GOALS, 2018-2030 (USD MILLION)
TABLE 180. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISEASE MODIFICATION, 2018-2030 (USD MILLION)
TABLE 181. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SYMPTOM RELIEF, 2018-2030 (USD MILLION)
TABLE 182. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DIAGNOSIS TESTS, 2018-2030 (USD MILLION)
TABLE 183. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 184. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MRI SCANS, 2018-2030 (USD MILLION)
TABLE 185. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 186. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 187. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 188. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 189. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 190. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 191. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 192. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 193. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 194. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 195. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 196. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 197. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 198. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 199. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 200. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 201. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 202. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, 2018-2030 (USD MILLION)
TABLE 203. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT GOALS, 2018-2030 (USD MILLION)
TABLE 204. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISEASE MODIFICATION, 2018-2030 (USD MILLION)
TABLE 205. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SYMPTOM RELIEF, 2018-2030 (USD MILLION)
TABLE 206. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DIAGNOSIS TESTS, 2018-2030 (USD MILLION)
TABLE 207. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 208. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MRI SCANS, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 216. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 217. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 218. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 219. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 220. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 221. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 222. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 223. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 224. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 225. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 226. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, 2018-2030 (USD MILLION)
TABLE 227. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT GOALS, 2018-2030 (USD MILLION)
TABLE 228. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISEASE MODIFICATION, 2018-2030 (USD MILLION)
TABLE 229. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SYMPTOM RELIEF, 2018-2030 (USD MILLION)
TABLE 230. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DIAGNOSIS TESTS, 2018-2030 (USD MILLION)
TABLE 231. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 232. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MRI SCANS, 2018-2030 (USD MILLION)
TABLE 233. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 247. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 249. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 250. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 251. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, 2018-2030 (USD MILLION)
TABLE 252. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT GOALS, 2018-2030 (USD MILLION)
TABLE 253. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISEASE MODIFICATION, 2018-2030 (USD MILLION)
TABLE 254. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SYMPTOM RELIEF, 2018-2030 (USD MILLION)
TABLE 255. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DIAGNOSIS TESTS, 2018-2030 (USD MILLION)
TABLE 256. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 257. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MRI SCANS, 2018-2030 (USD MILLION)
TABLE 258. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 272. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 274. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 275. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 276. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, 2018-2030 (USD MILLION)
TABLE 277. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT GOALS, 2018-2030 (USD MILLION)
TABLE 278. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISEASE MODIFICATION, 2018-2030 (USD MILLION)
TABLE 279. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SYMPTOM RELIEF, 2018-2030 (USD MILLION)
TABLE 280. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DIAGNOSIS TESTS, 2018-2030 (USD MILLION)
TABLE 281. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 282. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MRI SCANS, 2018-2030 (USD MILLION)
TABLE 283. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 284. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 285. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 286. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 287. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 288. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 289. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 290. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 291. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 292. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 293. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 294. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 295. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 296. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 297. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 298. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 299. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 300. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, 2018-2030 (USD MILLION)
TABLE 301. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT GOALS, 2018-2030 (USD MILLION)
TABLE 302. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISEASE MODIFICATION, 2018-2030 (USD MILLION)
TABLE 303. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SYMPTOM RELIEF, 2018-2030 (USD MILLION)
TABLE 304. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DIAGNOSIS TESTS, 2018-2030 (USD MILLION)
TABLE 305. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 306. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MRI SCANS, 2018-2030 (USD MILLION)
TABLE 307. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 308. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 309. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 310. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 311. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 312. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 313. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 314. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 315. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 316. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 317. INDIA DEVIC'S SYNDROME TREATMENT

Companies Mentioned

  • Accord Healthcare, Inc.
  • Alexion Pharmaceuticals, Inc by AstraZeneca PLC
  • Anant Pharmaceuticals Pvt. Ltd.
  • Apple Pharmaceuticals
  • Cadila Pharmaceuticals Limited
  • Chugai Pharma Taiwan Ltd.
  • Conscientia Industrial Co., Ltd
  • Evidentic GmbH
  • F. Hoffmann-La Roche Ltd
  • Healthy Life Pharma Pvt. Ltd.
  • Horizon Therapeutics plc by Amgen, Inc.
  • LEXICARE PHARMA PVT. LTD.
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Opexa Therapeutics, Inc.
  • Samsung Bioepis Co., Ltd. by Samsung Biologics
  • Teva Pharmaceutical Industries Ltd.
  • TG Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • West-Ward Pharmaceuticals Corp. by Hikma Pharmaceuticals PLC

Methodology

Loading
LOADING...

Related Topics

Related Reports

Neuromyelitis Optica - Pipeline Insight, 2025 - Product Image

Neuromyelitis Optica - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2025 - Product Image

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2025

  • Clinical Trials
  • 50 Pages
  • Global
From
Lennox-Gastaut Syndrome Treatment Market by Therapy Type, Route of Administration, Distribution Channel, End Users - Global Forecast 2025-2030 - Product Image

Lennox-Gastaut Syndrome Treatment Market by Therapy Type, Route of Administration, Distribution Channel, End Users - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Chronic Fatigue Syndrome Treatment Market by Treatment Type, Age Group, Mode of Administration, End User, Disease Type, Sales Channel - Global Forecast 2025-2030 - Product Image

Chronic Fatigue Syndrome Treatment Market by Treatment Type, Age Group, Mode of Administration, End User, Disease Type, Sales Channel - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 130 Pages
  • Global
From

About the Neuromyelitis Optica Drug Market

Neuromyelitis Optica (NMO) is a rare autoimmune disorder of the central nervous system (CNS) that affects the optic nerves and spinal cord. It is characterized by recurrent episodes of optic neuritis and transverse myelitis, which can lead to permanent vision loss and paralysis. Treatment of NMO is focused on reducing inflammation and preventing further damage to the CNS. Drugs used to treat NMO include corticosteroids, immunosuppressants, and monoclonal antibodies. Corticosteroids are used to reduce inflammation and prevent further damage to the CNS. Immunosuppressants are used to reduce the activity of the immune system and prevent further attacks. Monoclonal antibodies are used to target specific molecules involved in the autoimmune response. The NMO drug market is a rapidly growing segment of the CNS drug market. It is driven by the increasing prevalence of NMO and the development of new treatments. Companies in the NMO drug market include Biogen, Alexion Pharmaceuticals, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.